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Src kinase inhibition with dasatinib impairs
neutrophil function and clearance of
Escherichia coli infection in a murine model
of acute lung injury
James G. Macfarlane1* , David A. Dorward2, Marie-Hélène Ruchaud-Sparagano1, Jonathan Scott1,
Christopher D. Lucas2, Adriano G. Rossi2 and A. John Simpson1
Abstract
Background: Neutrophils rapidly respond to and clear infection from tissues, but can also induce tissue damage
through excessive degranulation, when acute inflammation proceeds unchecked. A number of key neutrophil
functions, including adhesion-dependent degranulation, are controlled by src family kinases. Dasatinib is a potent
src inhibitor used in treating patients with chronic myeloid leukaemia and treatment-resistant acute lymphoblastic
leukaemia. We hypothesized that dasatinib would attenuate acute inflammation by inhibiting neutrophil
recruitment, degranulation and endothelial cell injury, without impairing bacterial clearance, in a murine model of
bacteria-induced acute lung injury. C57BL/6 mice received intratracheal Escherichia coli, and were treated with
intraperitoneal dasatinib or control. Bacterial clearance, lung injury, and markers of neutrophil recruitment and
degranulation were measured. Separately, human blood neutrophils were exposed to dasatinib or control, and the
effects on a range of neutrophil functions assessed.
Results: Dasatinib was associated with a dose-dependent significant increase in E. coli in the mouse lung,
accompanied by impairment of organ function, reflected in significantly increased protein leak across the alveolar-
capillary membrane. However, the number of neutrophils entering the lung was unaffected, suggesting that
dasatinib impairs neutrophil function independent of migration. Dasatinib did not cause direct toxicity to human
neutrophils, but led to significant reductions in phagocytosis of E. coli, adhesion, chemotaxis, generation of
superoxide anion and degranulation of primary and secondary granules. However, no biologically important effect
of dasatinib on neutrophil degranulation was observed in mice.
Conclusions: Contrary to our starting hypothesis, src kinase inhibition with dasatinib had a detrimental effect on
bacterial clearance in the mouse lung and therefore does not represent an attractive therapeutic strategy to treat
primary infective lung inflammation. Data from human neutrophils suggest that dasatanib has inhibitory effects on
a range of neutrophil functions.
Keywords: Dasatinib, Src kinases, Neutrophil, Acute lung injury, acute respiratory distress syndrome, Pneumonia,
Phagocytosis, Infection
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Background
Neutrophils are key cellular mediators involved in rap-
idly responding to and clearing bacterial and fungal in-
fection. They are recruited early to the alveoli of patients
with pulmonary sepsis, acute lung injury (ALI) and acute
respiratory distress syndrome (ARDS) and their levels
correlate with degree of hypoxia, protein leak and clin-
ical outcome [1–3]. Early activation is achieved by coor-
dinated retention of circulating neutrophils by
endothelial cells, followed by neutrophil extravasation,
chemotaxis towards pathogens, and ingestion of these
pathogens in discrete phagosomes [4, 5]. Following
phagocytosis, neutrophil granules containing proteolytic
enzymes and machinery to generate reactive oxygen spe-
cies fuse with the phagosome, and killing of pathogens
proceeds [6–8]. Local, extracellular release of granule
products is potently anti-microbial and pro-
inflammatory, and can therefore be considered as a
physiological response when regulated. However, de-
pending on the size of the inflammatory stimulus
and the intensity of the neutrophil response, exces-
sive neutrophil granule release may become patho-
logical, with neutrophil proteases, cytokines and
reactive oxygen species (ROS) capable of direct and
indirect damage to the alveolar epithelium, leading
to increased permeability and protein-rich fluid leak
into the alveolar space [9, 10].
Several key neutrophil functions are regulated by src
kinases. Adhesion-dependent neutrophil degranulation is
regulated by the src kinases Hck and Fgr [11]. Neutro-
phils from mice deficient in Hck, Fgr and Lyn fail to de-
granulate or generate superoxide anion in response to
the bacterial virulence factor formyl methionine leucine
phenylalanine (fMLF) [12]. Activation of neutrophils via
cell surface Fc gamma receptors is also impaired in vivo
in Hck/Fgr/Lyn-null mice [13].
Dasatinib is a src kinase inhibitor that is widely used
in the treatment of Philadelphia chromosome-positive
chronic myeloid leukemia (CML) and treatment-
resistant acute lymphoblastic leukaemia (ALL), with the
potential for use in other malignancies being actively ex-
plored [14, 15]. In vitro, dasatinib blocks adhesion-
dependent neutrophil degranulation, with little effect on
chemotaxis, phagocytosis or bacterial killing at serum
concentrations of 50–100 nM, similar to physiological
concentrations measured in dasatinib-treated CML pa-
tients [16]. In a murine lipopolysaccharide (LPS)-in-
duced model of acute lung injury, dasatinib attenuated
lung inflammation but its effect was dependent on the
dose and the method of LPS delivery [17]. In the caecal
ligation and puncture (CLP) model of sepsis, pre- and
post-CLP administration of low dose dasatinib (1 mg/kg)
improved survival by 50% whereas survival was wors-
ened by a higher dose (10 mg/kg) [18].
Based on these in vitro and in vivo data, our starting
hypothesis was that src kinase inhibition with dasatinib
would prove beneficial in infective ALI/ARDS, by at-
tenuating neutrophilic inflammation, while maintaining
sufficient neutrophil phagocytic and killing capacity to
clear infection. Until now the effect of dasatinib in
models of direct bacterial lung infection has been poorly
characterized. We therefore sought to test our hypoth-
esis in an in vivo model of bacteria-induced acute lung
injury. As described below, our data did not support our
starting hypothesis, instead suggesting that dasatinib is
associated with reduced bacterial clearance.
Results
Dasatanib impairs lung clearance of E. coli infection and
increases alveolar leak
Experiments were performed to establish the time course
of E. coli-mediated recruitment of neutrophils to the al-
veolar space and pulmonary interstitium (see Supplemen-
tary Fig. 1, Additional file 1). A control experiment with
dasatinib alone at a dose of 1mg/kg or 10mg/kg, without
E. coli, showed that dasatinib itself did not cause alveolar
protein leak or increased cellular influx to the alveolar
space (Supplementary Fig. 2, Additional File 1). All subse-
quent in vivo experiments examined outcome measures
24 h after intratracheal (i.t.) instillation of 1 × 106 colony
forming units (cfu) E. coli.
Intraperitoneal (i.p.) dasatinib treatment at 0 h and 12 h
was associated with a dose-dependent increase in the con-
centration of bacteria retrieved from the lungs of mice
after i.t. administration of E. coli (delivered 30min after
the first dasatanib treatment), as compared to i.p. vehicle
control (Fig. 1). Extra-pulmonary isolation of E. coli was
observed in a small number of mice treated with the
higher dose of dasatinib, 10mg/kg. (Fig. 1).
The increased pulmonary bacterial load observed after
treatment with dasatinib at a dose of 10 mg/kg was asso-
ciated with reduced barrier function of the alveolar-
capillary membrane, as evidenced by significantly in-
creased concentrations of total protein in bronchoalveo-
lar lavage (BAL) fluid obtained 24 h after instillation of
bacteria (Fig. 2a). This observation was verified by meas-
uring IgM, as an example of a large molecule, the con-
centration of which is closely regulated in BAL fluid
(Fig. 2b).
Dasatinib has no effect on neutrophil recruitment or
degranulation
Disruption to the alveolar-capillary membrane can be
caused by infiltration of activated leukocytes [9, 10, 19].
However, dasatinib had no influence on the proportion
of leukocytes in BAL fluid, which was consistently ~ 85%
leucocytes and ~ 15% alveolar macrophages in control, 1
mg/kg or 10mg/kg dasatinib-treated mice, after E. coli
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treatment (Fig. 3). In keeping with this, concentra-
tions of pro- and anti-inflammatory cytokines in
BAL fluid were similar in the dasatinib and control
groups, with small increments in mean levels of
keratinocyte chemoattractant (KC) and tumour ne-
crosis factor (TNF) in BAL fluid from mice treated
with dasatinib at 10 mg/kg (see Supplementary Fig.
3, Additional file 1). No differences were observed in
the number of pulmonary interstitial neutrophils in
the dasatinib and control groups (see Supplementary
Fig. 4, Additional file 1).
Dasatinib appeared to have a minimal effect on de-
granulation of neutrophils in vivo (Fig. 4). No difference
in expression of neutrophil CD11b was found (Fig. 4a).
Myeloperoxidase (MPO) activity was increased after
treatment with dasatinib at a dose of 10 mg/kg, with no
effect on concentrations of extracellular MPO antigen
(Fig. 4b and c).
Dasatinib increases extrapulmonary toxicity
Extrapulmonary toxicity also appeared to be increased
by the higher concentration of dasatinib (10 mg/kg),
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Fig. 1 Effect of dasatinib pre-treatment on E. coli presence and survival in a, BAL fluid, b, lung homogenates, c, spleen, d, liver and e, peripheral
blood from mice exposed to i.t. E. coli. *p < 0.05, ***p < 0.001. Values were derived from two experiments (1 mg/kg or 10mg/kg dasatinib vs.
control administered at 0 and 12 h) using 8 mice per group. DAS = dasatinib
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Fig. 2 Effect of dasatinib pre-treatment on alveolar protein leak. a Total protein in BAL fluid. b Soluble IgM in BAL fluid from mice exposed to i.t. E. coli.
**p < 0.01. Values were derived from two experiments (1mg/kg or 10mg/kg dasatinib vs. control administered at 0 and 12 h) using 8 mice per group
Fig. 3 Effect of dasatinib pre-treatment on cellular influx into the alveolar space. a Total number of cells in BAL fluid. b Total number of
neutrophils in BAL fluid. c Representative cytocentrifuge preparations of BAL fluid (400x magnification) from mice exposed to i.t. E. coli. Values
were derived from two experiments (1 mg/kg or 10 mg/kg dasatinib vs. control administered at 0 and 12 h) using 8 mice per group
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which was associated with a consistent increase in
plasma levels of the hepatic enzyme alanine transamin-
ase (ALT), and a small but statistically significant
increase in concentrations of plasma lactate (see Supple-
mentary Fig. 5, Additional file 1).
Dasatinib inhibits a number of key neutrophil functions
in vitro
In an attempt to determine whether subtle effects on neu-
trophil function may contribute to the failure of bacterial
clearance in vivo, human neutrophils isolated from
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Fig. 4 Effect of dasatinib pre-treatment on markers of neutrophil degranulation in the alveolar space. a CD11b expression on BAL neutrophils, b
MPO activity and c MPO concentration in BAL fluid from mice exposed to i.t. E. coli. *p < 0.05, **p < 0.01. Values were derived from two
experiments (1 mg/kg or 10mg/kg dasatinib vs. control administered at 0 and 12 h) using 8 mice per group. GMF = geometric mean fluorescence
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Fig. 5 In vitro phagocytosis by isolated human blood neutrophils pre-treated with dasatinib. a MFI values of adherent neutrophils exposed to
pHrodo E. coli particles (EC) following pre-treatment with cytochalasin D or dasatinib. b Dose response of dasatinib treatment on neutrophil
phagocytosis of autologous serum-opsonized zymosan particles. ***p < 0.001. Values were derived from four experiments, each using neutrophils
from different healthy volunteers
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peripheral blood were exposed to dasatinib in vitro. Exper-
iments were carried out to determine whether dasatinib
had any direct toxic effects on neutrophils. Dasatinib had
no influence on release of lactate dehydrogenase (LDH),
or on neutrophil apoptosis (see Supplementary Fig. 6,
Additional file 1).
Dasatinib treatment resulted in significant impairment
in the capacity of neutrophils to phagocytose E. coli par-
ticles or zymosan (Fig. 5). Dasatinib was also associated
with significant reductions in neutrophil adhesion,
chemotaxis and superoxide anion generation (Fig. 6).
Dasatinib had small absolute effects on neutrophil de-
granulation (including that induced by E. coli LPS),
though at higher concentrations of dasatinib, statistically
significant inhibition of CD63 (primary granule) and
CD66b (secondary granule) was observed (Fig. 7).
Discussion
Our data indicate that src kinase inhibition with dasati-
nib is associated with dose-dependent impaired
clearance of E. coli in vivo and in vitro. To our know-
ledge this is the first in vivo experimental demonstration
modeling an increased susceptibility to pulmonary infec-
tion (with associated impairment of organ function) in-
duced by dasatinib.
Our findings suggest that the failure to clear E. coli
from the mouse lung is not attributable to impaired
neutrophil recruitment, as the numbers of neutrophils
entering the mouse lung were not significantly impaired
by dasatinib. The in vitro experiments however sug-
gested that neutrophil chemotaxis toward fMLF and
adhesion to tissue culture plastic is inhibited by dasati-
nib. Several explanations could underlie the apparent
discrepancy between the in vivo and in vitro findings –
for example, the range of chemotactic signals in vivo is
likely to be far broader and more complex. Further-
more, the stimulus strength of live bacteria may be too
potent for the doses of dasatinib reaching the lung in
situ to inhibit chemotaxis, adhesion and migration sig-
nificantly. Ultimately we feel that an effect of dasatinib
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Fig. 6 Effect of dasatinib on isolated human blood neutrophil adherence, chemotaxis and superoxide production in vitro. a Relative adherence of
stimulated neutrophils to tissue culture plastic and b relative 2-D chemotactic index of neutrophils towards formylated peptide, following pre-
treatment with dasatinib. c Extracellular superoxide production by stimulated neutrophils pre-treated with dasatinib. *p < 0.05, ***p < 0.001. Values
were derived from three (A + B) or five (C) experiments, each using neutrophils from different healthy volunteers
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on neutrophil recruitment and migration seems un-
likely to explain the observed impairment of clearance
of E. coli. These data are in contrast to the beneficial ef-
fects of src kinase inhibition with dasatinib in the CLP
sepsis model, where the lower dose of 1 mg/kg dasati-
nib administered 30 min before, 6 h and 24 h after CLP
(compared with our own time course of 30 min before
and 12 h after i.t. E. coli), improved survival and sepsis
severity, as well as reduced intraperitoneal bacterial
growth and spread [18]. Possible explanations for these
differences are the timings of dasatinib administration
after the acute inflammatory stimulus in the CLP model
and the differing stimulus intensity between the two
models. Similar to our findings, at the higher dose of
10 mg/kg dasatinib, there was a harmful effect in the
CLP model.
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Fig. 7 Effect of dasatinib on markers of degranulation on stimulated human neutrophils in heparinized blood. Flow cytometric analysis of CD63,
CD66b and CD11b expression on gated neutrophil population following pre-treatment with dasatinib and stimulation with a, cytochalasin B +
fMLF or b, LPS. *p < 0.05, **p < 0.01, ***p < 0.001. Values were derived from four experiments, each using neutrophils from different
healthy volunteers
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We believe that the in vitro inhibitory effects of dasati-
nib on degranulation, superoxide generation and chemo-
taxis are not borne out in our in vivo model of infection,
where the more likely explanation for impaired bacterial
clearance may relate to inhibitory effects of dasatinib on
phagocytosis. Dasatinib impaired ingestion of E. coli, and
also inhibited phagocytosis of zymosan particles in vitro.
The possibility remains that phagocytosis in vivo may
have been further inhibited by the impairment in neu-
trophil adhesion induced by dasatinib, which has also
been described by others [20–22]. Phagocytosis is more
efficient when neutrophils are adherent to a substratum
[23] and the implication, at least in vitro, is that dasati-
nib impairs tethering of neutrophils to surfaces. In con-
trast to dasatinib’s inhibition of phagocytosis, we did not
observe the hypothesized marked effect on neutrophil
degranulation.
In addition to suggesting a potential link to increased
infection risk in patients prescribed dasatinib, our results
provide an important caveat to recent studies suggesting
a potential therapeutic role for src kinase inhibitors in
inflammatory lung disorders. For example, src kinase in-
hibitors including dasatanib have been shown to signifi-
cantly reduce lung injury and inflammation in animal
models of acute lung injury [17, 24–26]. Similarly, bene-
ficial anti-inflammatory effects have been attributed to
dasatinib in experimental models of allergic asthma and
acute silicosis [27, 28]. The acute lung injury studies de-
scribed were all notable for using chemical and/or phys-
ical stimuli (rather than infective stimuli) to produce
lung damage. Our findings extend the existing literature
by suggesting that src kinase inhibitors deserve further
study as anti-inflammatory medications, while keeping
in mind that they may exacerbate infective causes of
lung inflammation, and increase the risk of secondary
infection.
We believe there are several strengths to this study.
These included the use of doses of dasatinib used in
comparable studies in the literature, and the reproduci-
bility of in vivo data (as reflected by similar results for
our separate control groups in Figs. 1, 2, 3), which in
turn increases confidence in the observed effects of dasa-
tinib. Furthermore, we used a broad range of assays in-
terrogating different human neutrophil functions, with a
view to understanding potential relevance in the human
setting.
We also recognize that there were limitations in our
study. A key consideration is whether our findings are
compatible with existing literature. In particular, the ele-
gant study by Gonçalves-de-Albuquerque et al. showed
that dasatinib reduced lung infection in a CLP model
[18]. There were fundamental differences between the
studies including strain of mouse, route of administra-
tion of dasatinib (gavage versus our i.p. route) and the
model (peritoneal, polymicrobial infection with second-
ary lung infection versus our direct, primary lung infec-
tion). The direct model consistently yields lung
parenchymal infection and milder systemic change, and
we opted for i.p. administration to avoid first-pass me-
tabolism effects. However, we acknowledge that gavage
more closely mimics the oral administration in patients,
and that our data cannot exclude a beneficial effect of
dasatinib in lung infection secondary to severe, systemic
sepsis. Our findings should therefore be considered in
the specific context of acute, primary pneumonia.
Secondly, it is possible that dasatinib has subtly differ-
ent effects on innate immunity in mice and in humans
[29, 30]. Our in vitro data in human neutrophils show
that dasatinib inhibits degranulation from primary and
secondary granules at higher concentrations, but clear
evidence for a similar effect in mice was lacking. Also,
pneumonia in patients is very rarely induced by a sud-
den bolus of infective material, as is traditionally used in
mouse models of pneumonia. Furthermore, we have in-
vestigated one potential pathogen here. While noting
these important limitations, we would defend the
current study on the grounds that, as described above, a
large prospective study of whether dasatinib is associated
with pneumonia during use in patients would be ex-
tremely difficult to fund and perform at present, and no
good rodent model imitating the true pathogenesis of
human pneumonia is currently available to our know-
ledge. As such, we believed it important to perform a
thorough assessment of one clearly relevant organism.
We therefore conclude that our study has demonstrated
proof of principle for in vivo susceptibility to pulmonary
infection associated with dasatinib (and established con-
ditions to explore this area further), but that these limi-
tations must be kept in mind.
Third, it is extremely difficult to know whether the
doses and concentrations of dasatanib used here are rep-
resentative of concentrations of dasatinib in patients’
lung tissue. Prospective clinical studies specifically seek-
ing to determine whether dasatanib increases the risk of
pneumonia in patients would require prohibitively large
numbers of subjects, and sub-studies to determine tissue
concentrations of dasatinib in the lung of infected pa-
tients would be extremely challenging. Certainly, no
such studies could be funded without supportive prelim-
inary data demonstrating proof of principle for a pro-
infective role of dasatanib in vivo (which we believe is
provided here). Therefore, for this initial study, we se-
lected doses used in comparable in vitro and in vivo
studies.
Fourth, we acknowledge that studies of src kinase in-
hibitors are necessarily complicated by variations in
tyrosine kinase inhibitor specificity. Dasatinib has inhibi-
tory effects on abl kinases in addition to src kinases [31,
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32]. The spectrum of src kinase inhibition for dasatinib
differs from that of other src kinase inhibitors used in
cancer research, such as PP1 or PP2. More specific indi-
vidual src family kinase inhibitors e.g. for Hck and Fgr
are not currently available, but would theoretically repre-
sent a potential way of selectively controlling individual
neutrophil granule subtype activity to maintain phago-
cytosis and killing functions, while attenuating harmful
extracellular degranulation [33]. However we selected
dasatinib precisely because of its clinical relevance. As
such we consider dasatinib to be the appropriate agent
for this study.
Conclusions
In summary, src kinase inhibition with dasatinib inhibits
clearance of E. coli from the mouse lung, without influ-
encing neutrophil recruitment. Instead, dasatinib impairs
the capacity of neutrophils to adhere and to phagocytose
E. coli. These data provide novel experimental evidence
suggesting that src kinase inhibition is unlikely to pro-
vide an effective treatment strategy for infective acute
lung injury.
Methods
In vivo acute lung infection model
C57BL/6 (female aged 8–12 weeks old; Charles River) re-
ceived 1 mg/kg or 10mg/kg dasatinib (Cambridge Bio-
science, Cambridge, UK) i.p. in dimethyl sulfoxide or
vehicle control. After 30 min, animals received i.t. E. coli
(serotype ATCC25922, grown to log phase) at a dose of
1 × 106 cfu as described [34]. Dasatinib or vehicle control
were re-administered i.p. at 12 h and samples obtained
at 24 h.
Assessment of bacterial load
At 24 h, BAL was performed with three aliquots of
800 μl sterile ice-cold saline administered i.t., and se-
quentially gently aspirated. 50 μl BAL from the first
lavage was kept for flow cytometric analysis of neu-
trophils and bacterial determination, with the remain-
der centrifuged at 300 g for 5 min, with cell-free
supernatant from the first lavage stored at -80 °C for
subsequent biochemical analysis. Blood samples were
taken by direct cardiac puncture and added to citrate
(as anticoagulant). Following lavage lungs were per-
fused with 20 ml phosphate-buffered saline and re-
moved en bloc prior to digestion using 5 mg/ml
collagenase D (Roche) in HBSS with cations [34].
Blood, BAL fluid and homogenized lung, liver and
spleen samples were all incubated overnight at 37 °C
on LB agar plates to determine bacterial colony
counts.
Quantification of neutrophils
After collagenase digestion of the right lung, red blood
cells were lysed (ACK lysis buffer, Invitrogen) and Fc-
mediated antibody binding reduced by incubation with
Fc block (Mouse BD Fc block, BD Bioscience). Lung di-
gest cells, BAL fluid cells and whole blood were incu-
bated with anti-CD45 and anti-Ly6G antibodies
(Biolegend, London, UK) for 30 min at 4 °C in the dark.
After addition of FACSlyse (BD Bioscience) cells were
resuspended in PBS and 50 μl flow-check fluorospheres
added (Beckman Coulter, Brea, CA) prior to flow cyto-
metric analysis.
Assays of neutrophil degranulation in vivo
BAL fluid cell samples were incubated with anti-Ly6G,
anti-CD63 and anti-CD11b antibodies (Biolegend,
London, UK), with flow analysis of neutrophil popula-
tions. CD63 is a membrane protein expressed on azuro-
philic (primary) granules and CD11b/CD18 (Mac-1) is a
β2 integrin expressed across specific (secondary), gelati-
nase (tertiary) and secretory vesicles [35]. Both can be
used as surrogate markers of degranulation when these
granules fuse with the extracellular membrane [36]. BAL
fluid MPO activity was quantified using the tetramethyl-
benzidine (TMB)/hydrogen peroxide (H2O2) colorimet-
ric assay [37], while MPO concentration was quantified
using a mouse MPO enzyme-linked immunosorbent
assay (ELISA) kit (R&D Systems, Abingdon, UK).
Quantification of BAL cytokines and alveolar protein
concentration
The pro- and anti-inflammatory cytokine profile of BAL
fluid was quantified using ELISA kits for KC, monocyte
chemoattractant protein-1 (MCP-1), TNF and interleu-
kin (IL)-10 (R&D Systems, Abingdon, UK) according to
the manufacturers’ instructions. Total protein was mea-
sured using a Pierce bicinchoninic acid assay kit (Life
Technologies, Paisley, UK) and BAL fluid IgM by
ELISA (eBioscience, Hatfield, UK).
Quantification of systemic toxicity
Plasma alanine transaminase (ALT) and lactate were
quantified according to manufacturers’ instructions
(Alpha Laboratories, Eastleigh, UK and Randox Labora-
tories, Crumlin, UK respectively) and adapted for use on
a Cobas Fara centrifugal analyzer (Roche Diagnostics,
Burgess Hill, UK).
Isolation of neutrophils from human blood
Neutrophils were isolated from the citrated whole blood
of healthy donors by dextran (Pharmacosmos, Holbaek,
Denmark) sedimentation and fractionation through iso-
tonic discontinuous Percoll (GE Healthcare, Little Chal-
font, UK) gradients, as described [38, 39]. Neutrophils
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were re-suspended at assay-dependent concentrations in
warmed Iscove’s modified Dulbecco’s medium (IMDM,
Life Technologies, Paisley, UK) with 1% autologous
serum. Only preparations yielding > 95% neutrophil pur-
ity with > 95% viability were used in experiments.
Neutrophil phagocytosis assay
Human neutrophils adherent to tissue culture plastic
were exposed to autologous serum-opsonized pH sensi-
tive pHrodo™ green E. coli Bioparticles for 30 min at
37 °C (Life Technologies, Paisley, UK), before analyzing
fluorescence at 585 nm.
In separate assays, neutrophils were exposed for 30
min at 37 °C to zymosan particles (derived from Saccha-
romyces cerevesiae) that had been opsonized using au-
tologous serum. Phagocytosis of zymosan particles was
quantified as described [40].
Neutrophil adhesion assay
Neutrophil adhesion to plastic was adapted from previ-
ously described methods [41]. Briefly, fresh neutrophils
in IMDM were added to a 24-well plate with 50 nM
fMLF (Sigma, Gillingham, UK) for 60 min to promote
adhesion. Non-adherent cells were washed off before ad-
herent cells were trypsinized, suspended with CountB-
right™ Absolute Counting Beads (Life Technologies,
Paisley, UK) and counted by flow cytometric analysis.
Neutrophil chemotaxis assay
Two-dimensional ‘under agarose’ chemotaxis towards
fMLF was measured as described [42].
Neutrophil superoxide assay
The extracellular release of superoxide anion by neu-
trophils in response to priming by platelet-activating
factor (PAF, Sigma, Gillingham, UK) and activation by
fMLF was quantified using the cytochrome C reduc-
tion assay [43].
In vitro neutrophil degranulation assays
Fresh heparinized blood samples were stimulated with
10 μM cytochalasin B (Sigma, Gillingham, UK)/1 μM
fMLF or E. coli 026:B6-derived LPS (Sigma, Gillingham,
UK) to induce neutrophil degranulation before incubat-
ing with anti-CD63, anti-CD66b (localized on secondary
neutrophil granules) and anti-CD11b antibodies for flow
analysis, as described [36].
Neutrophil toxicity assays
Direct cytotoxicity of dasatinib on isolated neutrophils
was quantified using a Roche LDH cytotoxicity kit
(Roche, Sussex, UK), according to the manufacturer’s in-
structions. Cytocentrifuge preparations of isolated neu-
trophils exposed to dasatinib for 24 h and stained with
Giemsa (Sigma, Gillingham, UK) were assessed for mor-
phological changes consistent with apoptosis.
Statistical analysis
Flow cytometry data were analyzed using Flojo version
10.0.7 (Ashland, OR, US). Results, expressed as individual
data points with mean ± s.d. (in vivo data) or mean (in vitro
data), were analyzed using GraphPad Prism (Graphpad
Software, La Jolla, CA, US), by repeated measures one-way
analysis of variance or a Friedman test with a post-hoc
Dunn’s test, or an unpaired t-test, as appropriate. Statistical
significance was considered to be at the level of p < 0.05.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12950-020-00261-5.
Additional file 1 Intratracheal instillation of E. coli resulted in the
anticipated time-dependent accumulation of neutrophils in the pulmon-
ary interstitium and alveolar space, with marked inflammation present at
24 h, and near resolution by 48 h (Supplementary Fig. 1). Dasatinib alone,
without i.t. E. coli, caused no cellular influx into the alveolar space or al-
veolar protein leak (Supplementary Fig. 2). When E. coli-infected mice
were treated with either dasatinib or control at 0 and 12 h, small mean
increments were seen in BAL fluid concentrations of the pro-
inflammatory cytokines KC and TNF in association with dasatinib at 10
mg/kg (Supplementary Fig. 3), but no differences were observed in the
numbers of neutrophils in the pulmonary interstitium (Supplementary
Fig. 4). A small increase in blood neutrophils was observed in association
with the higher dose of dasatinib studied (10 mg/kg) (Supplementary
Fig. 4). Treatment of E. coli-infected mice resulted in a significant increase
in blood levels of lactate and of the hepatic enzyme ALT (Supplementary
Fig. 5). When dasatinib or control was applied directly to isolated human
blood neutrophils, no difference was observed in the release of LDH or
on the rate of neutrophil apoptosis (Supplementary Fig. 6). Figure S1
Kinetics of neutrophil influx into the lung interstitium and alveolar space
following i.t. instillation of E. coli in mice. n = 2–3 mice per time point.
Figure S2 Effect of dasatinib pre-treatment alone on cellular influx to the
alveolar space and alveolar protein leak. n = 1 mouse per condition. Fig-
ure S3 Effect of dasatinib pre-treatment on the pro/anti-inflammatory
cytokine profile of the alveolar space. A, KC, B, MCP-1, C, TNF and D, IL-
10 concentrations in BAL fluid from mice exposed to i.t. E. coli. *p < 0.05,
**p < 0.01, ****p < 0.0001. Values were derived from two experiments (1
mg/kg or 10 mg/kg dasatinib vs. control administered at 0 and 12 h)
using 8 mice per group. Figure S4 Effect of dasatinib pre-treatment on
blood neutrophilia and neutrophil influx into lung interstitium. A, % neu-
trophils of all leukocytes in blood and B, total number of neutrophils in
lung homogenates from mice exposed to i.t. E. coli. *p < 0.05. Values were
derived from two experiments (1 mg/kg or 10 mg/kg dasatinib vs. control
administered at 0 and 12 h) using 8 mice per group. Figure S5 Effect of
dasatinib pre-treatment on markers of extrapulmonary toxicity. A, plasma
lactate and B, plasma ALT concentrations in mice exposed to i.t. E. coli.
**p < 0.01, ****p < 0.0001. Values were derived from two experiments (1
mg/kg or 10 mg/kg dasatinib vs. control administered at 0 and 12 h)
using 8 mice per group. Figure S6 Effect of dasatinib on the viability
and apoptosis of isolated human blood neutrophils. A, cytotoxicity of
dasatinib, as measured by extracellular LDH release, expressed as a per-
centage of the sample lysed using Triton. B, apoptosis rates after 24 h of
culture with PMA (phorbol myristate acetate) or dasatinib, as measured
by cell morphological characteristics under light microscopy. **p < 0.01.
Values were derived from three (A) or four (B) experiments, each using
neutrophils from different healthy volunteers.
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